NAV

Recombinant Human Thrombopoietin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Recombinant Human Thrombopoietin
Accession Number
DB16364
Description

Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.1,2 This drug is used in the treatment of thrombocytopenia.

Type
Biotech
Groups
Investigational
Synonyms
  • rhTPO
  • rHuTPO
External IDs
  • Recombinant Human Thrombopoietin

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Recombinant human thrombopoietin has similar biological functions as endogenous thrombopoietin.2 It activates the thrombopoietin receptor MPL.1 This therapy has potential roles in hematopoietic stem and progenitor cell regeneration and is currently being investigated against relapsed immune thrombocytopenia, hematopoietic injury, and acute severe thrombocytopenia in sepsis.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Wang C, Zhang B, Wang S, Zhang J, Liu Y, Wang J, Fan Z, Lv Y, Zhang X, He L, Chen L, Xia H, Li Y, Pei X: Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation. Sci Rep. 2015 Sep 25;5:12993. doi: 10.1038/srep12993. [PubMed:26403418]
  2. Zhou Z, Feng T, Xie Y, Huang P, Xie H, Tian R, Qian B, Wang R: The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial). BMC Infect Dis. 2019 Sep 6;19(1):780. doi: 10.1186/s12879-019-4388-2. [PubMed:31492102]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentThrombocytopenia1
4RecruitingTreatmentPrimary Immune Thrombocytopenia1
4RecruitingTreatmentThrombocytopenia1
4Unknown StatusTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Delayed Platelet Engraftment / Myeloablative1
3CompletedPreventionSarcomas1
3CompletedTreatmentHematologic Diseases / Thrombocytopenia1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura / Purpura3
3CompletedTreatmentImmune Thrombocytopenia1
3CompletedTreatmentImmune Thrombocytopenia / Pregnant State1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 17, 2020 15:51 / Updated on December 19, 2020 20:42